AEB071

Phase 2Completed

0 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Uveitis

Conditions

Uveitis, Posterior Uveitis, Panuveitis

Trial Timeline

Jul 1, 2008 → —

NCT ID

NCT00615693

About AEB071

AEB071 is a phase 2 stage product being developed by Novartis for Uveitis. The current trial status is completed. This product is registered under clinical trial identifier NCT00615693. Target conditions include Uveitis, Posterior Uveitis, Panuveitis.

What happened to similar drugs?

3 of 20 similar drugs in Uveitis were approved

Approved (3) Terminated (8) Active (9)

✅Ixekizumab Prefilled SyringeEli LillyApproved

✅AdalimumabAbbVieApproved

✅Topical Prednisolone Acetate 1%Ocular TherapeutixApproved

🔄4 mg CLS-TA Suprachoriodal InjectionClearside BiomedicalPhase 3

🔄Baricitinib + AdalimumabEli LillyPhase 3

🔄adalimumabAbbViePhase 3

🔄Adalimumab + Prednisone + PlaceboAbbViePhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (7)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01430416	Phase 1	Completed	Dec 20, 2011	May 22, 2019	Uveal Melanoma
NCT01402440	Phase 1	Terminated	Nov 1, 2011	Apr 1, 2014	Diffuse Large B-Cell Lymphoma
NCT00615693	Phase 2	Completed	Jul 1, 2008	—	Uveitis
NCT00545259	Phase 1	Completed	Oct 1, 2007	—	de Novo Liver Transplantation
NCT00492869	Phase 1/2	Completed	Jan 1, 2007	—	Kidney Transplantation
NCT00416546	Phase 1	Completed	Oct 1, 2006	Oct 1, 2007	Healthy
NCT00409929	Phase 1	Completed	Jun 1, 2006	—	Healthy

Competing Products

20 competing products in Uveitis

See all competitors

Product	Company	Stage	Hype Score
triamcinolone acetonide (Triesence®)	Clearside Biomedical	Phase 1/2	22
4 mg CLS-TA Suprachoriodal Injection	Clearside Biomedical	Phase 3	30
Baricitinib + Adalimumab	Eli Lilly	Phase 3	44
Ixekizumab Prefilled Syringe	Eli Lilly	Approved	39
adalimumab	AbbVie	Phase 3	40
Adalimumab + Prednisone + Placebo	AbbVie	Phase 3	40
Adalimumab + Prednisone + Placebo	AbbVie	Phase 3	40
Adalimumab	AbbVie	Approved	43
FTY720 + Oral Corticosteroid	Novartis	Phase 2	27
AIN457	Novartis	Phase 3	32
Myfortic	Novartis	Pre-clinical	22
AIN457 + AIN457 + Placebo AIN457	Novartis	Phase 3	32
LFG316 + Conventional Therapy	Novartis	Phase 2	35
Ranibizumab	Novartis	Phase 2	35
AIN457 + Placebo	Novartis	Phase 3	32
AIN457 + AIN457 + AIN457 + Placebo	Novartis	Phase 3	32
AIN457 + AIN457 + AIN457 + Placebo	Novartis	Phase 3	32
Myfortic + Decortin	Novartis	Phase 3	40
AIN457 + AIN 457 + AIN457	Novartis	Phase 2	35
AIN457 + AIN457 + AIN457 + Placebo	Novartis	Phase 3	32